Another headquarters is enabled in Singapore-Sichuan High-tech Innovation Park!

Date:2021-09-28 Views:1248

     

On September 27-28, “2021 West Smart Medical Industry Summit” was held in CDHT. On the opening ceremony of the summit, AstraZeneca officially announced the opening of its West China headquarters in CDHT. Chengdu International Life Science Innovation Campus, and AstraZeneca Modern Innovation Center for Integrated Chinese and Western Medicines also settled in CDHT at the same time.

 

B I O T I A N F U

2021 West Smart Medical Industry Summit

"Ecological integration for a better future"

With the theme of “ecological integration for a better future”,

this summit aims to integrate the resources of multiple platforms including the government, enterprises, scientific research institutions,

capitals and hospitals

and promote the development of west medical ecosystem.

 

 

The submit attracted over 50 senior executives of well-known pharmaceutical companies at home and abroad, TOP clinical deliverable transformation organizations and west leading enterprises including AstraZeneca, WATSON HEALTH, Luye Life Sciences, Allergan, Asymchem, and Genetron, as well as representatives from academic, research, medical and investment sectors to discuss the innovative development of west medicine and health industry.

 

 

West China Headquarters of AstraZeneca is officially opened

 

As an important agenda of the opening ceremony of the summit,

AstraZeneca announced the opening of

its West China headquarters.

 

# West China headquarters of AstraZeneca

AstraZeneca is a global scientific pharmaceutical company that is focusing on research and development, production and marketing of prescription drugs with its main attention to the medical fields of cancer, cardiovascular, kidney and metabolism, respiratory and immune diseases. With its headquarter in Cambridge, UK, AstraZeneca's business covers over 100 countries around the world.

 

West China headquarters of AstraZeneca is the first headquarters project with complete functions set up by a multinational pharmaceutical company in Sichuan Province, and it will be responsible for company operation management, sales, marketing and other affairs in ten provinces, cities and autonomous regions including Sichuan, Chongqing, Shaanxi, Hubei, Xinjiang, Gansu, Guizhou, Qinghai, Ningxia and Tibet.

 

 

CDHT continues to optimize the business environment and provide a good element guarantee and supporting support for the development of the medical and health industry. In the future, AstraZeneca will continuously increase the investment to build a platform for multi-party communication and value connection, and unite the forces of political, industrial, academic, research, medical and investment sectors to explore more innovative cooperation models so as to better meet the growing health needs of local patients.

                                                                                                         - Wang Lei, Global Executive Vice President of AstraZeneca

President of International Business and China Region

 

 

With the opening of West China Headquarters of AstraZeneca,

Chengdu International Life Science Innovation Campus,

and AstraZeneca Modern Innovation Center for Integrated Chinese and Western Medicines

also settled in CDHT at the same time

to jointly help Chengdu to build

an international medical and health industry ecosystem.

 

 

 

Chengdu International Life Science Innovation Campus

“Chengdu International Life Science Innovation Campus” is a life science innovation incubation platform jointly built by CDHT and AstraZeneca, which is committed to providing a one-stop innovation enabling platform of project implementation, incubation and commercialization for innovative enterprises at home and abroad.

 

On the site of the summit, 9 enterprises in the first group including Huiyi Tianxia and EclinCloud officially signed to settle. Besides, the Campus was also designated as "an alliance activity base of Chengdu medicine and health industry ecosystem" by Chengdu Medicine and Health Industry Alliance, and the awarding ceremony was also held. The Campus will become a core activity space for medicine innovation of the Alliance.

 

 

and AstraZeneca Modern Innovation Center for Integrated Chinese and Western Medicines

At “AstraZeneca Modern Innovation Center for Integrated Chinese and Western Medicines”, AstraZeneca will unit partners of political, industrial, academic, research, medical and investment sectors through the innovation cooperation model of “experts research, industry innovation and achievement integration”, combine local industrial advantages to incubate a new model of "integrated TCM and western medicine + smart medicine", accelerate to develop innovative solutions with TCM elements integrating diagnosis and treatment, speed up the promotion and application and help smart development of TCM and western medicine combination.

 

Ten partners including Homed Medical Device Co., Ltd., Sinocare and Aisono officially signed to settle.

 

 

Other items

 

CDHT has reached cooperation intention with AstraZeneca and China Capital Investment Group (CCIG) on the establishment of innovation fund, and plans to participate in AstraZeneca CCIG Medical Industry Fund and improve the effect of CDHT on investment promotion through cooperation of political, industrial and investment sectors.

 

AstraZeneca signed a cooperation agreement with West China Hospital Sichuan University to jointly promote R&D of original new drugs.

 

AstraZeneca signed “Strategic Cooperation Memorandum for Smart Community Chronic Disease Management” with CDHT, devoted to comprehensive health management of patients with chronic diseases by primary medical institutions.

 

AstraZeneca Pharmaceutical (Chengdu) Trading Co., Ltd. was officially opened. Since then, AstraZeneca's innovative imported products will be officially sold across the country from Chengdu.

 

Phase II of Chengdu Advanced Medical Science Center

 

 

Highlights on the summit forum

 

 

The conference lasted for two days.

There are several steps on the summit,

including closed-door meeting, keynote speech, summit dialogue, roundtable forum and sub-forums.

The participants will conduct in-depth discussion and communication on

the most popular topics

such as policy interpretation, pharmaceutical innovation, industrial development and Internet-based medical treatment.

 

 

 

Keynote speech

Wei Yuquan - academician of Chinese Academy of Sciences, Wang Mingwei - Director of the National Center for Drug Screening, and Shan Junbao - President of China Capital Investment Group delivered a keynote speech respectively on innovation discovery to clinical value transformation, development trend of life sciences frontiers and pharmaceutical industry, and investment trend of life health industry.

 

Summit dialogue

Li Weimin - Director of West China Hospital Sichuan University, Li Jin - President of HitGen, Li Shaochun - General Manager of IBM WATSON HEALTH in China region, and Yang Dajun - President of Ascentage Pharma conducted summit dialogues around the theme of “integration of smart medical innovation and industrial”.

 

 

Roundtable dialogue

Cao Guoxiong - Founding partner of Puhua Capital, Wang Sizhen - Co-founder of Genetron, Liu Gexin - President of Kelun Industry Group, Chen Bo - President of Conmed Biosciences, Hong Hao - President of Asymchem, and Wang Qinghan - President of Chengdu Kanghua Biological Products Co., Ltd. conducted a roundtable dialogue around the theme that “industrial integration enables new ecology of the medical industry”.

 

Sub-forums

The four sub-forums deeply discussed the hot issues of the industry around the themes “Local innovation, a way out for biomedicine”, “New industry opportunities under medical insurance reform”, “Innovate TCM and guide the future - smart medicine forum of integrated Chinese and Western medicines” and “Forum of new development and new ideas of Internet-based medicine”, providing new thoughts for the intelligent development of medical and health industry in west China in the post-epidemic era.

 

 

B I O T I A N F U

CDHT

Construct "five-chain integration" bioindustry ecocircle

 

As the main base of Chengdu medical and health industry development, CDHT has been committed to constructing the "five-chain integration" bioindustry ecocircle, including industrial chain, factor chain, supply chain, value chain and innovation chain.

 

Focusing on the construction of Chengdu Tianfu International Biotown, CDHT vigorously promotes the development of the medical and health industry. Key industrial clusters such as modern TCM, chemical medicine, biological agents and medical instruments have taken shape, and more than 3,000 pharmaceutical enterprises have settled in CDHT. CDHT is in the front rank in terms of comprehensive competitiveness among the national biomedical industrial parks.

 

 

CDHT is seizing the strategic opportunity for the construction of the Chengdu-Chongqing economic circle, and aiming at critical links and key fields such as vaccine R&D for serious infectious diseases, precision medicine, GCP and R&D of high-end medical instruments to boost the rapid development of medical and health industry ecosystem.

                                                                                                            - Responsible person for CDHT Biological Industry Development Bureau

 

 

 

CDHT will continue to create

a market-based, law-based and international business environment

and build a life cycle service system for enterprises.

While providing better guarantees for enterprises,

it will enhance the construction of a platform system for scientific and technological innovation,

practically promote transformation of substantive deliverables,

and enable innovation and upgrading of medical and health industry.

 

Chengdu Advanced Medical Science Center where West China headquarters of AstraZeneca settles is Phase II of Tianfu Life Science Park.

 

 

Located in No. 2222, Xinchuan Road, CDHT, Phase II of Tianfu Life Science Park was put into operation by the end of 2018, covering an area of 167 mu, with the total building area of 294,000 m2. As a school-local cooperation project between Sichuan University and CDHT, Phase II is built into Chengdu Advanced Medical Science Center, and positioned as a new core and source of advanced medical innovation and development in Chengdu, which focuses on cross-border and integrated new business forms such as frontier medicine, precision medicine, smart health, and medical cosmetology. It attaches importance to promoting the transformation of relevant scientific research deliverables of Sichuan University and West China Hospital Sichuan University. At present, it has introduced 40 high-level R&D projects and 10 enterprise projects established by professors of Sichuan University.

 

 

Source: CDHT

 

 

  • Phase One

    Tel:028-85975146

    Add:No. 88, Keyuan South Road, High-tech Zone, Chengdu

  • Phase Two

    Tel:028-85326166

    Add:No. 2222, Xinchuan Road, High-tech Zone, Chengdu

  • Phase Three

    Tel:028-58976074

    Add:No. 2222, Xinchuan Road, High-tech Zone, Chengdu

Park WeiChart